The group's principal activity is to develop respiratory therapies and pulmonary drug delivery products. The group also performs research and development of aerosolized formulations of its humanized surfactant technology to treat respiratory conditions such as asthma. The group's product, surfaxin(R), is an engineered humanized surfactant. Surfaxin(R) is currently in two phase 3 clinical trials for respiratory distress syndrome in premature infants (rds), a phase 3 clinical trial for meconium aspiration syndrome in full-term infants (mas), and a phase 2 clinical trial for acute lung injury/acute respiratory distress syndrome in adults (ali/ards).
